#biosimilars
Aurobindo Pharma: Strong dose of growth opportunities
Aurobindo’s near-term growth driven by US/Lannett, Europe, and Pen-G, with long-term upside from biologics/biosimilars and margin-led expansion.
Lupin eyes $500 mn biosimilars revenue in medium term, to ramp capacity
The company plans to soon start the funding process for its oncology spin-off, Kaveri Therapeutics, which houses two specialised oncology programmes
Global Biopharmaceutical Processing Equipment & Consumables Market is Anticipated to Cross the USD 110 Billion Mark by 2034 | DelveInsight
The biopharmaceutical processing equipment & consumables market is witnessing robust growth, driven by the rising production of biologics, biosimilars, vaccines, and advanced cell and gene therapies. Increasing investments in biopharmaceutical manufacturing c…
Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal Manchanda
India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and consumer healthcare. While US FDA approvals for complex generics remain a challenge, innovation and contract manufacturi…
Bio-Thera Solutions' Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States
GUANGZHOU, China, May 18, 2026 /PRNewswire/ -- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Accord BioPharma, Inc, the U.S. specialty division of Intas Pharmac…
Cipla bets on fast-growing biosimilars market, to steadily add products: CEO
Cipla is developing a biosimilars pipeline, with plans to add 1-2 products yearly for the next five years. The drugmaker is investing in R&D, especially for developed markets, to build out a strong pipeline across respiratory, peptides as well as complex …
Emcure doubling down on biosimilars pipeline: MD Satish Mehta
Emcure currently has six biosimilars in the market, launched through its subsidiary Gennova Biopharmaceuticals. While it has developed these in-house so far, the drugmaker will also scout for partners with products not in their pipeline, for commercialisation…
Rituximab Biosimilars Market Trastuzumab Biosimilars Market Research Analysis Report 2026: $6.2 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
Key opportunities in the rituximab biosimilars market include the launch of new biosimilar formulations, expansion of subcutaneous delivery options, and increasing adoption in emerging markets. Rising prevalence of non-Hodgkin's lymphoma and autoimmune diseas…
Trastuzumab Biosimilars Market Analysis Report 2026: $24.48 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
The trastuzumab biosimilars market is expanding due to increasing cancer prevalence, loss of patent exclusivity, and cost-effective therapies. Opportunities abound in biosimilar expansions, physician confidence, untapped regional markets, and favorable reimbu…
Sun Pharma shares rally 9% in two days after $12-bn Organon deal. Here's what Morgan Stanley, other brokerages say
Sun Pharmaceutical Industries' shares surged nearly 9% after announcing the $11.75 billion acquisition of Organon & Co., a global leader in women's health. The deal diversifies Sun Pharma's portfolio into women's health and biosimilars, with analysts from Mor…
Why Sun Pharma’s massive Organon buyout is winning over investors where Lupin, Biocon failed
Sun Pharma’s acquisition of Organon marks a pivot toward biosimilars, utilizing a cheap valuation and strong cash reserves to avoid the chronic post-merger stock slumps seen by Indian rivals.